The DNA Sensor AIM2 Mediates Psoriasiform Inflammation by Inducing Type 3 Immunity

Psoriasis is a chronic and recurrent inflammatory skin disease characterized by abnormal proliferation and differentiation of keratinocytes and activation of immune cells. However, the molecular driver that triggers this immune response in psoriatic skin remains unclear. The inflammation-related gene absent in melanoma 2 (AIM2) was identified as a susceptibility gene/locus associated with psoriasis. In this study, we investigated the role of AIM2 in the pathophysiology of psoriasis. We found elevated levels of mitochondrial DNA in patients with psoriasis, along with high expression of AIM2 in both the human psoriatic epidermis and a mouse model of psoriasis induced by topical imiquimod (IMQ) application. Genetic ablation of AIM2 reduced the development of IMQ-induced psoriasis by decreasing the production of type 3 cytokines (such as IL-17A and IL-23) and infiltration of immune cells into the inflammatory site. Furthermore, we demonstrate that IL-17A induced AIM2 expression in keratinocytes. Finally, the genetic absence of inflammasome components downstream AIM2, ASC, and caspase-1 alleviated IMQ-induced skin inflammation. Collectively, our data show that AIM2 is involved in developing psoriasis through its canonical activation.

Citing Articles

Pulmozyme Ameliorates LPS-Induced Lung Fibrosis but Provokes Residual Inflammation by Modulating Cell-Free DNA Composition and Controlling Neutrophil Phenotype.

Alekseeva L, Senkova A, Sounbuli K, Savin I, Zenkova M, Mironova N Biomolecules. 2025; 15(2).

PMID: 40001601 PMC: 11853346. DOI: 10.3390/biom15020298.

References

Zuo X, Sun L, Yin X, Gao J, Sheng Y, Xu J . Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis. Nat Commun. 2015; 6:6793. PMC: 4403312. DOI: 10.1038/ncomms7793. View

Ni X, Lai Y . Keratinocyte: A trigger or an executor of psoriasis?. J Leukoc Biol. 2020; 108(2):485-491. DOI: 10.1002/JLB.5MR0120-439R. View

Lood C, Blanco L, Purmalek M, Carmona-Rivera C, De Ravin S, Smith C . Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016; 22(2):146-53. PMC: 4742415. DOI: 10.1038/nm.4027. View

Stutz A, Golenbock D, Latz E . Inflammasomes: too big to miss. J Clin Invest. 2009; 119(12):3502-11. PMC: 2786809. DOI: 10.1172/JCI40599. View

Glaccum M, Stocking K, Charrier K, Smith J, Willis C, Maliszewski C . Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol. 1997; 159(7):3364-71. View

Mahil S, Capon F, Barker J . Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2015; 38(1):11-27. PMC: 4706579. DOI: 10.1007/s00281-015-0539-8. View

Benhadou F, Mintoff D, Del Marmol V . Psoriasis: Keratinocytes or Immune Cells - Which Is the Trigger?. Dermatology. 2018; 235(2):91-100. DOI: 10.1159/000495291. View

Martin D, Towne J, Kricorian G, Klekotka P, Gudjonsson J, Krueger J . The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2012; 133(1):17-26. PMC: 3568997. DOI: 10.1038/jid.2012.194. View

Li B, Tsoi L, Swindell W, Gudjonsson J, Tejasvi T, Johnston A . Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. J Invest Dermatol. 2014; 134(7):1828-1838. PMC: 4057954. DOI: 10.1038/jid.2014.28. View

10.

Yao Y, Richman L, Morehouse C, de Los Reyes M, Higgs B, Boutrin A . Type I interferon: potential therapeutic target for psoriasis?. PLoS One. 2008; 3(7):e2737. PMC: 2481274. DOI: 10.1371/journal.pone.0002737. View

11.

Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S . AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J Clin Immunol. 2013; 33(5):925-37. DOI: 10.1007/s10875-013-9881-6. View

12.

Rauch I, Deets K, Ji D, von Moltke J, Tenthorey J, Lee A . NAIP-NLRC4 Inflammasomes Coordinate Intestinal Epithelial Cell Expulsion with Eicosanoid and IL-18 Release via Activation of Caspase-1 and -8. Immunity. 2017; 46(4):649-659. PMC: 5476318. DOI: 10.1016/j.immuni.2017.03.016. View

13.

Chung I, Yuan S, OuYang C, Hu S, Lin H, Huang K . EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment. Cytokine. 2019; 127:154951. DOI: 10.1016/j.cyto.2019.154951. View

14.

Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang Y, Homey B . Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449(7162):564-9. DOI: 10.1038/nature06116. View

15.

Jones J, Kayagaki N, Broz P, Henry T, Newton K, ORourke K . Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci U S A. 2010; 107(21):9771-6. PMC: 2906881. DOI: 10.1073/pnas.1003738107. View

16.

Bae J, Jo S, Kim S, Lee J, Jeong J, Kang J . Circulating Cell-Free mtDNA Contributes to AIM2 Inflammasome-Mediated Chronic Inflammation in Patients with Type 2 Diabetes. Cells. 2019; 8(4). PMC: 6524162. DOI: 10.3390/cells8040328. View

17.

Cao T, Yuan X, Fang H, Chen J, Xue K, Li Z . Neutrophil extracellular traps promote keratinocyte inflammation via AIM2 inflammasome and AIM2-XIAP in psoriasis. Exp Dermatol. 2022; 32(4):368-378. DOI: 10.1111/exd.14711. View

18.

Tomalin L, Russell C, Garcet S, Ewald D, Klekotka P, Nirula A . Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. J Allergy Clin Immunol. 2019; 145(3):922-932. DOI: 10.1016/j.jaci.2019.10.041. View

19.

Poli V, Zanoni I . Neutrophil intrinsic and extrinsic regulation of NETosis in health and disease. Trends Microbiol. 2022; 31(3):280-293. PMC: 9974585. DOI: 10.1016/j.tim.2022.10.002. View

20.

Morizane S, Yamasaki K, Muhleisen B, Kotol P, Murakami M, Aoyama Y . Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2011; 132(1):135-43. PMC: 3220926. DOI: 10.1038/jid.2011.259. View